Beta-propeller protein-associated neurodegeneration

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:329284OMIM:300894G23.0
Who is this for?
Show terms as
18Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Beta-propeller protein-associated neurodegeneration (BPAN) is a rare genetic brain disorder that belongs to a group of conditions called neurodegeneration with brain iron accumulation (NBIA). It is also known as static encephalopathy of childhood with neurodegeneration in adulthood (SENDA). In BPAN, iron builds up abnormally in certain parts of the brain, particularly areas involved in movement and thinking. The disease is caused by changes (mutations) in the WDR45 gene, which plays a role in a cell-cleaning process called autophagy. BPAN typically shows two distinct phases. In childhood, affected individuals experience developmental delays, intellectual disability, and often seizures. Children may have trouble learning to walk and talk, and their development tends to plateau early. For many years, the condition may appear relatively stable. Then, usually in adolescence or early adulthood, a second phase begins with progressive worsening. This includes movement problems such as dystonia (involuntary muscle contractions) and parkinsonism (stiffness, slowness, and tremor), along with a decline in thinking and memory skills (dementia). There is currently no cure for BPAN, and treatment focuses on managing symptoms. Seizures are treated with anti-seizure medications, and movement problems may be partially managed with medications used for Parkinson's disease or dystonia. Physical therapy, occupational therapy, and speech therapy are important parts of care. Research into iron chelation therapy and other approaches is ongoing, but no disease-modifying treatment is yet available.

Also known as:

Key symptoms:

Developmental delay in childhoodIntellectual disabilitySeizures or epilepsyDelayed speech and language skillsDifficulty walking or unsteady gaitInvoluntary muscle contractions (dystonia)Stiffness and slowness of movement (parkinsonism)TremorDecline in thinking and memory skills (dementia) in adulthoodSleep disturbancesBehavioral difficultiesDifficulty with fine motor skillsEye movement abnormalitiesLoss of previously acquired skills in adulthood

Clinical phenotype terms (22)— hover any for plain English
Frontal release signsHP:0000743Progressive encephalopathyHP:0002448Iron accumulation in brainHP:0012675Iron accumulation in substantia nigraHP:0012678
Inheritance

X-linked dominant

Carried on the X chromosome; a single copy can cause the condition

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Beta-propeller protein-associated neurodegeneration.

View clinical trials →

No actively recruiting trials found for Beta-propeller protein-associated neurodegeneration at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Beta-propeller protein-associated neurodegeneration community →

Specialists

18 foundView all specialists →
LA
Laura A Adang
PHILADELPHIA, PA
Specialist
3 Beta-propeller protein-associated neurodegeneration publications
HD
Holly Dubbs
PHILADELPHIA, PA
Specialist
3 Beta-propeller protein-associated neurodegeneration publications
NT
Nivedita Thakur
HOUSTON, TX
Specialist
3 Beta-propeller protein-associated neurodegeneration publications
EK
Emma Kotes
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
SW
Sarah Woidill
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
EY
Eric Yang
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
VS
Vanessa Smith
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
KP
Kristy Pucci
PHILADELPHIA, PA
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
FG
Francesco Gavazzi
Specialist
3 Beta-propeller protein-associated neurodegeneration publications
SP
Samuel R Pierce
Specialist
3 Beta-propeller protein-associated neurodegeneration publications
JV
Joseph Vithayathil
PHILADELPHIA, PA
Specialist
3 Beta-propeller protein-associated neurodegeneration publications
TD
Thomas Klopstock, Prof. Dr.
Specialist
PI on 3 active trials
MR
Mitchell J Rechtzigel
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
PP
Prithvi R Patthi
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
KK
Krishna S Karia
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
BM
Brandon L Meyerink
Specialist
2 Beta-propeller protein-associated neurodegeneration publications
BK
Bhatia P Kailash
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Beta-propeller protein-associated neurodegeneration.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Beta-propeller protein-associated neurodegenerationForum →

No community posts yet. Be the first to share your experience with Beta-propeller protein-associated neurodegeneration.

Start the conversation →

Latest news about Beta-propeller protein-associated neurodegeneration

No recent news articles for Beta-propeller protein-associated neurodegeneration.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage of BPAN is my child or family member currently in, and what changes should I watch for?,What is the best approach to managing seizures, and what should I do if a seizure lasts more than 5 minutes?,Are there any clinical trials or experimental treatments available for BPAN right now?,What therapies (physical, occupational, speech) do you recommend, and how often?,Should other family members be tested for the WDR45 gene change?,How will we monitor for disease progression, and how often should brain MRI be repeated?,What resources or support groups can you connect us with for families affected by BPAN or NBIA?

Common questions about Beta-propeller protein-associated neurodegeneration

What is Beta-propeller protein-associated neurodegeneration?

Beta-propeller protein-associated neurodegeneration (BPAN) is a rare genetic brain disorder that belongs to a group of conditions called neurodegeneration with brain iron accumulation (NBIA). It is also known as static encephalopathy of childhood with neurodegeneration in adulthood (SENDA). In BPAN, iron builds up abnormally in certain parts of the brain, particularly areas involved in movement and thinking. The disease is caused by changes (mutations) in the WDR45 gene, which plays a role in a cell-cleaning process called autophagy. BPAN typically shows two distinct phases. In childhood, aff

How is Beta-propeller protein-associated neurodegeneration inherited?

Beta-propeller protein-associated neurodegeneration follows a x-linked dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Beta-propeller protein-associated neurodegeneration typically begin?

Typical onset of Beta-propeller protein-associated neurodegeneration is childhood. Age of onset can vary across affected individuals.

Which specialists treat Beta-propeller protein-associated neurodegeneration?

18 specialists and care centers treating Beta-propeller protein-associated neurodegeneration are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.